Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries | Zendy

Ying Huang | Zendy; Zoe Moodie | Zendy; Michal Juraska | Zendy; Youyi Fong | Zendy; Lindsay N. Carpp | Zendy; Laurent Chambonneau | Zendy; Diana L Coronel | Zendy; Gustavo H. Dayan | Zendy; Carlos A. DiazGranados | Zendy; Peter B. Gilbert | Zendy

Open Access

Immunobridging efficacy of a tetravalent dengue vaccine against dengue and against hospitalized dengue from children/adolescents to adults in highly endemic countries

Author(s) -

Ying Huang,

Zoe Moodie,

Michal Juraska,

Youyi Fong,

Lindsay N. Carpp,

Laurent Chambonneau,

Diana L Coronel,

Gustavo H. Dayan,

Carlos A. DiazGranados,

Peter B. Gilbert

Publication year - 2020

Publication title -

transactions of the royal society of tropical medicine and hygiene

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.725

H-Index - 105

eISSN - 1878-3503

pISSN - 0035-9203

DOI - 10.1093/trstmh/traa154

Subject(s) - dengue fever , dengue vaccine , titer , dengue virus , medicine , serotype , virology , pediatrics , virus

The recombinant tetravalent live-attenuated dengue vaccine based on the YF 17D vaccine virus backbone (CYD-TDV) demonstrated vaccine efficacy (VE) against symptomatic, virologically confirmed dengue of any serotype from month 13 to month 25 (VCD-DENV-AnyM13→M25) in the CYD14 (2-14-y-olds) and CYD15 (9-16-y-olds) phase 3 trials. Fifty percent plaque reduction neutralization test (PRNT50) titers are a potential surrogate for immunobridging VE to adults.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research